168 related articles for article (PubMed ID: 18456868)
61. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
Corvol JC; Anzouan-Kacou JB; Fauveau E; Bonnet AM; Lebrun-Vignes B; Girault C; Agid Y; Lechat P; Isnard R; Lacomblez L
Arch Neurol; 2007 Dec; 64(12):1721-6. PubMed ID: 18071034
[TBL] [Abstract][Full Text] [Related]
62. Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide.
Růzicka E; Línková H; Penicka M; Ulmanová O; Nováková L; Roth J
J Neurol; 2007 Nov; 254(11):1575-8. PubMed ID: 17712588
[TBL] [Abstract][Full Text] [Related]
63. Risk assessment and follow-up of valvular regurgitation in Parkinson patients treated with cabergoline.
Fietzek UM; Riedl L; Ceballos-Baumann AO
Parkinsonism Relat Disord; 2012 Jun; 18(5):654-6. PubMed ID: 21908226
[No Abstract] [Full Text] [Related]
64. Cardiovascular magnetic resonance imaging-derived mitral valve geometry in determining mitral regurgitation severity.
Fernandes AM; Rathi V; Biederman RW; Doyle M; Yamrozik JA; Willians RB; Hedge V; Graunt S; Aras R
Arq Bras Cardiol; 2013 Jun; 100(6):571-8. PubMed ID: 23657269
[TBL] [Abstract][Full Text] [Related]
65. A case of constrictive pericarditis during cabergoline treatment for hyperprolactinaemia.
Löndahl M; Nilsson A; Lindgren H; Katzman P
Eur J Endocrinol; 2008 Apr; 158(4):583-5. PubMed ID: 18362307
[TBL] [Abstract][Full Text] [Related]
66. Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma.
Doğan BA; Arduc A; Tuna MM; Berker D; Demirci N; Demirtaş S; Çiçekcioğlu H; Güler S
Endocr Metab Immune Disord Drug Targets; 2016; 16(1):47-55. PubMed ID: 26924497
[TBL] [Abstract][Full Text] [Related]
67. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
Dewey RB; Reimold SC; O'Suilleabhain PE
Arch Neurol; 2007 Mar; 64(3):377-80. PubMed ID: 17353380
[TBL] [Abstract][Full Text] [Related]
68. A case of iatrogenic severe mitral regurgitation.
D'Aloia A; Piovanelli B; Rovetta R; Bonadei I; Vizzardi E; Curnis A; Metra M
Monaldi Arch Chest Dis; 2013 Sep; 80(3):133-6. PubMed ID: 24818320
[TBL] [Abstract][Full Text] [Related]
69. B-type natriuretic peptide and cardiovalvulopathy in Parkinson disease with dopamine agonist.
Watanabe H; Hirayama M; Noda A; Ito M; Atsuta N; Senda J; Kaga T; Yamada A; Katsuno M; Niwa T; Tanaka F; Sobue G
Neurology; 2009 Feb; 72(7):621-6. PubMed ID: 19221295
[TBL] [Abstract][Full Text] [Related]
70. Cabergoline-induced tricuspid regurgitation: Case report and review of literature.
Bhat MH; Mushtaq S; Saba S; Saif R; Ali G
Indian J Endocrinol Metab; 2011 Apr; 15(2):137-9. PubMed ID: 21731877
[TBL] [Abstract][Full Text] [Related]
71. Valvular heart disease in hyperprolactinemic patients treated with low doses of cabergoline.
Córdoba-Soriano JG; Lamas-Oliveira C; Hidalgo-Olivares VM; Tercero-Martínez A; Barambio-Ruíz M; Salas-Nieto J
Rev Esp Cardiol (Engl Ed); 2013 May; 66(5):410-2. PubMed ID: 24775830
[No Abstract] [Full Text] [Related]
72. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
Simonis G; Fuhrmann JT; Strasser RH
Mov Disord; 2007 Oct; 22(13):1936-42. PubMed ID: 17659636
[TBL] [Abstract][Full Text] [Related]
73. Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy.
Italiano D; Bianchini E; Ilardi M; Cilia R; Pezzoli G; Zanettini R; Vacca L; Stocchi F; Bramanti P; Ciurleo R; Di Lorenzo G; Polimeni G; de Luise C; Ross D; Rijnbeek P; Sturkenboom M; Trifirò G
J Neural Transm (Vienna); 2015 Jun; 122(6):799-808. PubMed ID: 25230720
[TBL] [Abstract][Full Text] [Related]
74. [Treatment with cabergoline in Parkinson disease can cause heart damage. Continuous treatment requires clinical and echocardiographic check ups].
Lökk J
Lakartidningen; 2007 Oct 3-9; 104(40):2892-4. PubMed ID: 17966806
[No Abstract] [Full Text] [Related]
75. The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists.
Rasmussen VG; Østergaard K; Dupont E; Poulsen SH
Mov Disord; 2011 Apr; 26(5):801-6. PubMed ID: 21671508
[TBL] [Abstract][Full Text] [Related]
76. [An aortic insufficiency diagnosed under cabergoline].
Chagué F; Belleville I; Boujon B; Petit JM
Ann Cardiol Angeiol (Paris); 2009 Jun; 58(3):189-91. PubMed ID: 18656845
[TBL] [Abstract][Full Text] [Related]
77. In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology.
Droogmans S; Franken PR; Garbar C; Weytjens C; Cosyns B; Lahoutte T; Caveliers V; Pipeleers-Marichal M; Bossuyt A; Schoors D; Van Camp G
Eur Heart J; 2007 Sep; 28(17):2156-62. PubMed ID: 17636306
[TBL] [Abstract][Full Text] [Related]
78. Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease.
Levin J; Neudert J; Zwermann L; Näbauer M; Bötzel K
J Neurol; 2011 Nov; 258(11):2097-9. PubMed ID: 21562724
[No Abstract] [Full Text] [Related]
79. [Valvular heart disease in relation to the treatment of hyperprolactinemia with dopamine agonists].
Gabalec F; Čáp J; Radocha J
Vnitr Lek; 2017; 63(9):561-565. PubMed ID: 29120651
[TBL] [Abstract][Full Text] [Related]
80. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: A joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology.
Steeds R; Stiles C; Sharma V; Chambers J; Lloyd G; Drake W
Clin Endocrinol (Oxf); 2019 May; 90(5):662-669. PubMed ID: 30818417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
